{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T15:55:53Z","timestamp":1792425353532,"version":"4.5.0"},"reference-count":17,"publisher":"Japanese Society of Internal Medicine","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2020,3,15]]},"DOI":"10.2169\/internalmedicine.3295-19","type":"journal-article","created":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T22:04:43Z","timestamp":1574373883000},"page":"849-853","source":"Crossref","is-referenced-by-count":3,"title":["Development of Disseminated Tuberculosis with Intestinal Involvement due to Adalimumab Administration Despite Latent Tuberculosis Treatment"],"prefix":"10.2169","volume":"59","author":[{"given":"Kozo","family":"Ikuta","sequence":"first","affiliation":[{"name":"Division of Gastroenterology, Shinko Memorial Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumiko","family":"Ota","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Shinko Memorial Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigenobu","family":"Kuroki","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Shinko Memorial Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihide","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Shinko Memorial Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eri","family":"Senda","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Shinko Memorial Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saki","family":"Mukohara","sequence":"additional","affiliation":[{"name":"The Center for Rheumatic Diseases, Shinko Memorial Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soshi","family":"Takahashi","sequence":"additional","affiliation":[{"name":"The Center for Rheumatic Diseases, Shinko Memorial Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Monden","sequence":"additional","affiliation":[{"name":"Department of Respiratory Center, Shinko Memorial Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihisa","family":"Fukuda","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Seno","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunichi","family":"Kumagai","sequence":"additional","affiliation":[{"name":"The Center for Rheumatic Diseases, Shinko Memorial Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Shio","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Shinko Memorial Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Ai JW, Ruan QL, Liu QH, Zhang WH. Updates on the risk factors for latent tuberculosis reactivation and their managements. Emerg Microbes Infect 5: e10, 2016.","DOI":"10.1038\/emi.2016.10"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Ramos GP, Stroh G, Al-Bawardy B, Faubion WA, Papadakis KA, Escalante P. Outcomes of treatment for latent tuberculosis infection in patients with inflammatory bowel disease receiving biologic therapy. Inflamm Bowel Dis 24: 2272-2277, 2018.","DOI":"10.1093\/ibd\/izy133"},{"key":"3","unstructured":"3. Parra Ruiz J, Ortego Centeno N, Raya Alvarez E. Development of tuberculosis in a patient treated with infliximab who had received prophylactic therapy with isoniazid. J Rheumatol 30: 1657-1658, 2003."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Raychaudhuri S, Shmerling R, Ermann J, Helfgott S. Development of active tuberculosis following initiation of infliximab despite appropriate prophylaxis. Rheumatology (Oxford) 46: 887-888, 2007.","DOI":"10.1093\/rheumatology\/kel447"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Bourikas LA, Kourbeti IS, Koutsopoulos AV, Koutroubakis IE. Disseminated tuberculosis in a Crohn&apos;s disease patient on anti-TNF alpha therapy despite chemoprophylaxis. Gut 57: 425; author reply -6, 2008.","DOI":"10.1136\/gut.2007.132407"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement. Am J Respir Crit Care Med 161 (4 Pt 2): S221-S247, 2000.","DOI":"10.1164\/ajrccm.161.supplement_3.ats600"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Amorim RF, Viegas ERC, Carneiro AJV, et al. Superiority of interferon gamma assay over tuberculin skin test for latent tuberculosis in inflammatory bowel disease patients in Brazil. Dig Dis Sci 64: 1916-1922, 2019.","DOI":"10.1007\/s10620-019-5475-3"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Lin PL, Myers A, Smith L, et al. Tumor necrosis factor neutralization results in disseminated disease in acute and latent <i>Mycobacterium tuberculosis<\/i> infection with normal granuloma structure in a cynomolgus macaque model. Arthritis Rheum 62: 340-350, 2010.","DOI":"10.1002\/art.27271"},{"key":"9","unstructured":"9. Ai JW, Zhang S, Ruan QL, et al. The risk of tuberculosis in patients with rheumatoid arthritis treated with tumor necrosis factor-alpha antagonist: a metaanalysis of both randomized controlled trials and registry\/cohort studies. J Rheumatol 42: 2229-2237, 2015."},{"key":"10","unstructured":"10. Theis VS, Rhodes JM. Review article: minimizing tuberculosis during anti-tumour necrosis factor-alpha treatment of inflammatory bowel disease. Aliment Pharmacol Ther 27: 19-30, 2008."},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. DeSimone JA, Pomerantz RJ, Babinchak TJ. Inflammatory reactions in HIV-1-infected persons after initiation of highly active antiretroviral therapy. Ann Intern Med 133: 447-454, 2000.","DOI":"10.7326\/0003-4819-133-6-200009190-00013"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Sueki H, Mizukawa Y, Aoyama Y. Immune reconstitution inflammatory syndrome in non-HIV immunosuppressed patients. J Dermatol 45: 3-9, 2018.","DOI":"10.1111\/1346-8138.14074"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Watanabe S, Kaneko Y, Kawamoto H, et al. Paradoxical response with increased tumor necrosis factor-alpha levels to anti-tuberculosis treatment in a patient with disseminated tuberculosis. Respir Med Case Rep 20: 201-204, 2017.","DOI":"10.1016\/j.rmcr.2017.02.011"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Garcia Vidal C, Rodriguez Fernandez S, Martinez Lacasa J, et al. Paradoxical response to antituberculous therapy in infliximab-treated patients with disseminated tuberculosis. Clin Infect Dis 40: 756-759, 2005.","DOI":"10.1086\/427941"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Lwin N, Boyle M, Davis JS. Adalimumab for corticosteroid and infliximab-resistant immune reconstitution inflammatory syndrome in the setting of TB\/HIV coinfection. Open Forum Infect Dis 5: ofy027, 2018.","DOI":"10.1093\/ofid\/ofy027"},{"key":"16","unstructured":"16. Walker NF, Stek C, Wasserman S, Wilkinson RJ, Meintjes G. The tuberculosis-associated immune reconstitution inflammatory syndrome: recent advances in clinical and pathogenesis research. Curr Opin HIV AIDS 13: 512-521, 2018."},{"key":"17","unstructured":"17. Dasgupta A, Singh N, Bhatia A. Abdominal tuberculosis: a histopathological study with special reference to intestinal perforation and mesenteric vasculopathy. J Lab Physicians 1: 56-61, 2009."}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/59\/6\/59_3295-19\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,21]],"date-time":"2020-03-21T03:40:51Z","timestamp":1584762051000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/59\/6\/59_3295-19\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,15]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.3295-19","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,15]]}}}